Organon & Co.

pharmaceutical company

OGN NYSE ISIN US68622V1061 SEC CIK 1821825 LEI 549300AMCKY57OK2CO56
Follow Organon & Co. Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.6B −1.7% vs same quarter last year
Net income $164M +2.5% vs same quarter last year
EPS, diluted $0.60 −1.6% vs same quarter last year
Operating cash flow $370M +40.2% vs same quarter last year
Revenue by quarter
$1.6B
$1.5B
$1.6B
$1.6B
$1.5B
$1.5B
$1.6B
$1.6B
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
$0$2B$4B$6B$8BFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$6.2B$187M
FY24$6.4B$864M
FY23$6.3B$1B
FY22$6.2B$917M
FY21$6.3B$1.4B
FY20$6.5B$2.2B
FY19$7.8B$3.2B
FY18--
MarginsShare of revenue
  • Gross margin
  • Net margin
0%20%40%60%80%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginNet margin
FY2553.3%3%
FY2458%13.5%
FY2359.8%16.3%
FY2262.8%14.9%
FY2162.2%21.4%
FY2067.6%33.1%
FY1970.8%41.4%
FY18--
Free cash flowOperating cash flow minus capital expenditure
$0$1B$2B$3BFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$538M
FY24$764M
FY23$548M
FY22$662M
FY21$2B
FY20$2B
FY19$2.9B
FY18-
Returned to shareholdersDividends paid and shares bought back
$0$100M$200M$300MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearDividends
FY25$88M
FY24$297M
FY23$294M
FY22$290M
FY21$145M
FY20$0
FY19$0
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Organon & Co.
  • Healthcare median
−100%−50%0%50%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOrganon & Co.Healthcare median
FY253%−30.6%
FY2413.5%−47%
FY2316.3%−58%
FY2214.9%−80.4%
FY2121.4%−71.9%
FY2033.1%−62.2%
FY1941.4%−46.3%
FY18-−49.6%